AM Resources Corp is a mining company engaged in the exploration of coal, hydrocarbons, and gold mining sites located in Colombia. Its main project is the Mina Luz property, a 40-hectare coal-producing project southwest of Popayan and 150 km southwest of Cali in which it has an approximately 80% interest. It also holds interests in the Rio Negro asphaltite, Esperanza Property, and Mico gold projects. Geographically, it derives a majority of revenue from United States.
Nearly 2,000 industry-sponsored infectious disease clinical trials have been initiated, ongoing, or planned globally between 2020 and 2024, with Asia-Pacific region dominating at 43% of global trials.
Biogen has begun dosing in the Phase 3 TRANSCEND study evaluating felzartamab against placebo in approximately 120 adult kidney transplant recipients with late antibody-mediated rejection (AMR).
Recce Pharmaceuticals expects completion of its Phase II ABSSSI trial by the end of the year, with early results showing positive outcomes in treated patients.
The AMR Accelerator, comprising 98 organizations, is advocating for sustained investment in antibiotic development and antimicrobial resistance (AMR) research by governments and the private sector.